Statins are often prescribed drugs for the treatment of dyslipidemia and used by millions of people worldwide every day. They act as inhibitors of HMG-CoA reductase, a key enzyme in the synthesis of cholesterol, thus preventing a major cardiovascular event and stroke. Although they are very potent in lowering cholesterol, especially LDL, statins can cause unwanted side effects. Toxic myopathy is the most commonly reported side effect of statins and it is estimated that approximately one quarter of statin users experience this side effect. Clinical presentation can be very different, from asymptomatic elevation of CK to rarely but potentially fatal rabdomiolysis. As the most common symptom patients report muscle weakness which predominantly affects proximal muscle groups. Other symptoms may include tiredness, myalgia, cramps or changes in muscular trophies. Along with this is often the intolerance of physical effort. Statin intolerance is more susceptible to genetic predisposition involving genomic polymorphisms that encode statin transporter into a cell. Discontinuation of statin therapy is the first step in the treatment of this myopathy with possible supplements of vitamin D and coenzyme Q10. If symptoms and elevated CK concentrations continue to persist despite the discontinuation of statin therapy, physician should suspect potential immune mediated non-proliferating myositis, characterized by the presence of anti-HMGCR antibodies, whose diagnosis requires muscle biopsy and electromyography. After withdrawal of symptoms, consideration should be given to the benefit of re-introduction of statin in therapy and the individual pro-active risk of potential major coronary events and atherosclerotic stroke. If statins are necessary in therapy and are poorly tolerated by patients, consideration should be given to the possibility of replacing statins with non-statin drugs to treat dyslipidemia.